12:00 AM
Jun 15, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Orplatna satraplatin: Preliminary Phase II data

Data from 16 evaluable patients in an ongoing, open-label Phase II trial of Orplatna plus Avastin bevacizumab and prednisone showed that 7 patients had a PSA decline, with a >=30% decline observed in 4 patients. Eleven patients progressed after a median of six...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >